MannKind Expands Commercial Capabilities With Two New Hires
April 19 2016 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
today announced two senior appointments to its commercial
organization. Joining the Company are Joseph Saldanha as Vice
President of Marketing and Agustin (Tino) Quintero as Vice
President of Market Value, Access and Trade. Both will report
to Michael Castagna, MannKind’s Chief Commercial Officer.
“I am excited to have Joe and Tino join my team
to help us transition into a commercial organization with dedicated
capabilities,” said Michael Castagna. “Each brings a wealth
of experience in commercialization, diabetes and pharmaceutical
product launches, and their skills will be critical as MannKind
moves forward with our commercial plans.”
Matthew Pfeffer, Chief Executive Officer of
MannKind added, “The expansion of Mike’s organization with these
two key roles supports MannKind’s business objectives for 2016 and
beyond. Under Joe and Tino’s leadership, MannKind can develop
strong relationships with payors that benefit patients, and produce
innovative and focused marketing and sales programs that establish
MannKind’s market presence with Technosphere®-based products.”
Mr. Saldanha has worked in the diabetes space
for over 13 years, in both U.S. and global roles. He has
experience marketing oral anti-diabetic medications, insulins (both
injectable and inhaled), and medical devices. Mr. Saldanha
commercialized Sanofi’s Lantus® in the Intercontinental
Region. After returning to the U.S., he was part of the team
that commercialized the Lantus SoloSTAR® pen. In addition to
heading up Sanofi’s strategy and medical education teams, he was
responsible for all hospital business. Mr. Saldanha launched
an initiative with Certified Diabetes Educators® to train patients
in diabetes and the appropriate use of insulin. Prior to
that, Mr. Saldanha served as Director of Business Development for
the insulin delivery device business at Johnson and Johnson
Diabetes (LifeScan®/Animas®). More recently, he worked in the
biosimilars business with Pfizer in New York. Mr. Saldanha
holds a Bachelor of Science from Drexel University and a Master of
Science from the University of Pennsylvania.
Mr. Quintero has 18 years of experience in
bio-pharmaceutical market access as well as a proven record of
achieving commercial excellence. He joins MannKind from
AbbVie, a global biopharmaceutical company, where he served as
National Managed Care Executive. In this role, Mr. Quintero
was responsible for negotiating AbbVie’s portfolio of products
(including Humira®) while developing contracting and pricing
strategies for hepatitis C, multiple sclerosis and oncology product
launches. Prior to that, he held integral leadership roles in
sales and account management at Vertex Pharmaceuticals, including
oversight of the commercial launch of Incivek®, their first
commercial product. Earlier, he was part of Gilead Sciences and
Sandoz's leadership teams, responsible for sales, product launches
and market access for both commercial and government payers.
Mr. Quintero holds a Bachelor of Science in economics from Florida
International University.
Members of the investment community are reminded
of the upcoming conference call to discuss the company's general
commercialization strategy in the US, being held later today (April
19, 2016) at 5:00 pm (Eastern Time).
To participate in the live call by telephone,
please dial (888) 224-7957 or (303) 223-4394 and use the
participant passcode: 21809665. Those interested in listening to
the conference call live via the Internet may do so by visiting the
Company's website at http://www.mannkindcorp.com.
A telephone replay of the call will be
accessible for approximately 14 days following completion of the
call by dialing (800) 633-8284 or (402) 977-9140 and use the
participant passcode: 21809665. A replay will also be
available on MannKind's website for 14 days.
The trademarks mentioned in this release are the
property of their respective owners.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD)
focuses on the discovery and development of therapeutic products
for patients with diseases such as diabetes. MannKind
maintains a website at www.mannkindcorp.com to which MannKind
regularly posts copies of its press releases as well as additional
information about MannKind. Interested persons can subscribe on the
MannKind website to e-mail alerts that are sent automatically when
MannKind issues press releases, files its reports with the
Securities and Exchange Commission or posts certain other
information to the website.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties, including
statements regarding MannKind’s ability to directly commercialize
pharmaceutical products. Words such as “believes”,
“anticipates”, “plans”, “expects”, “intend”, “will”, “goal",
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
are based upon the MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
ability to generate significant product sales for MannKind,
difficulties or delays in obtaining regulatory feedback or
completing and analyzing the results of clinical studies,
MannKind’s ability to manage its existing cash resources or raise
additional cash resources, stock price volatility and other risks
detailed in MannKind’s filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2015 and subsequent periodic reports on Form
10-Q and current reports on Form 8-K. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact:
Rose Alinaya
SVP, Finance
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024